Increased mucosal tumour necrosis factor α production in Crohn's disease can be downregulated ex vivo by probiotic bacteria

Gut

Volumn 51, Issue 5, 2002, Pages 659-664

  Borruel, N ^a   Carol, M ^a   Casellas, F ^a   Antolin M ^a   De Lara, F ^a   Espin E ^a   Naval, J ^a   Guarner, F ^a   Malagelada, J R ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE; PROBIOTIC AGENT; PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; ENTERITIS; ENZYME RELEASE; ESCHERICHIA COLI; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; INTESTINE LYMPH; INTESTINE MUCOSA; LACTOBACILLUS; LACTOBACILLUS CASEI; MALE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; COCULTURE TECHNIQUES; CROHN DISEASE; CULTURE TECHNIQUES; ESCHERICHIA COLI; FEMALE; HUMANS; INTESTINAL MUCOSA; L-LACTATE DEHYDROGENASE; LACTOBACILLUS; LACTOBACILLUS CASEI; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PROBIOTICS; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036839109     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.51.5.659     Document Type: Article

References (43)

1. Podolsky DK. Inflammatory Bowel Disease. N Engl J Med 1991;325:928-37.
2. Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut 1997;40:443-8.
3. Targan SR. Biology of inflammation in Crohn's disease: Mechanisms of action of anti-TNF-α therapy. Can J Gastroenterol 2000;14(suppl C):13-6C.
4. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-α, IL-6, and IL-1 β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993;94:174-81.
5. Breese EJ, Michie CA, Nicholis SW, et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455-66.
6. Reimund JM, Wittersheim C, Dumont S, et al. Increased production of tumour necrosis factor-α, interleukin-1β, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996;39:684-9.
7. Dionne S, Hiscott J, D'Agata I, et al. Quantitative PCR analysis of TNF-α and IL-1β mRNA levels in pediatric IBD mucosal biopsies. Dig Dis Sci 1997;42:1557-66.
8. Woywodt A, Ludwig D, Neustock P, et al. Mucosal cytokine expression, cellular markers and adhesion molecules in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1999;11:267-76.
9. Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 1997;349:521-4.
10. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-α for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
11. Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22-8.
12. D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European Multicenter Trial. Gastroenterology 1999;116:1029-34.
13. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
14. Ricart E, Panaccione R, Loftus EV, et al. Successful management of Crohn's disease of the ileoanal pouch with infliximab. Gastroenterology 1999;117:429-32.
15. Nikolaus S, Raedler A, Kuhbacker T, et al. Mechanisms in failure of infliximab for Crohn's disease. Lancet 2000;356:1475-9.
16. Plevy SE, Landers CJ, Prehn J, et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997;159:6276-82.
17. Ina K, Itoh J, Fukushima K, et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 1999;163:1081-90.
18. Fiocchi C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 1998;115:182-206.
19. Pirzer U, Schönhaar A, Fleischer B, et al. Reactivity of infiltrating T lymphocytes with microbial antigens in Crohn's disease. Lancet 1991;33B:1238-9.
20. Macpherson A, Khoo UY, Forgacs I, et al. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996;38:365-75.
21. Videla S, Vilaseca J, Guarner F, et al. Role of intestinal microflora in chronic inflammation and ulceration of the rat colon. Gut 1994;35:1090-7.
22. García-Lafuente A, Antolín M, Guarner F, et al. Incrimination of anaerobic bacteria in the induction of experimental colitis. Am J Physiol 1997;272:G10-15.
23. Mourelle M, Salas A, Guarner F, et al. Stimulation of transforming growth factor-β1 by enteric bacteria in the pathogenesis of rat intestinal fibrosis. Gastroenterology 1998;114:519-26.
24. Kühn R, Löhler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263-74.
25. Madsen KL, Doyle JS, Jewell LD, et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999;116:1107-14.
26. Umesaki Y, Setoyama H, Matsumoto S, et al. Expansion of alpha beta T-cell receptor-bearing intestinal intraepithelial lymphocytes after microbial colonization in germ-free mice and its independence from thymus. Immunology 1993;79:32-7.
27. Helgeland L, Vaage JT, Rolstad B, et al. Microbial colonization influences composition and T-cell receptor V beta repertoire of intraepithelial lymphocytes in rat intestine. Immunology 1996;89:494-501.
28. Haller D, Bode C, Hammes WP, et al. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut 2000;47:79-87.
29. Guerin-Danan C, Chabanet C, Pedone C, et al. Milk fermented with yogurt cultures and Lactobacillus casei compared with yogurt and gelled milk: Influence on intestinal microflora in healthy infants. Am J Clin Nutr 1998;67:111-17.
30. Pedone CA, Bernabeu AO, Postaire ER, et al. The effect of supplementation with milk fermented by Lactobacillus casei (strain DN-114 001) on acute diarrhoea in children attending day care centres. Int J Clin Pract 1999;53:179-84.
31. Osset J, Bartolome RM, Garcia E, et al. Assessment of the capacity of Lactobacillus to inhibit the growth of uropathogens and block their adhesion to vaginal epithelial cells. J Infect Dis 2001;1B3:485-91.
32. Ochman H, Selander RK. Standard reference strains of Escherichia coli from natural populations. J Bacteriol 1984;154:690-3.
33. Carol M, Lambrechts A, Van Gossum A, et al. Spontaneous secretion of interferon γ and interleukin 4 by human intraepithelial and lamina propria gut lymphocytes. Gut 1998;42:643-9.
34. Krieg AF, Gorton S, Henry JB. Effect of temperature on activity and lactate optima of LDH isoenzymes. Clin Chim Acta 1967;17:363-6.
35. Finnie IA, Dwarakanath AD, Taylor BA, et al. Colonic mucin synthesis is increased by sodium butyrate. Gut 1995;36:93-9.
36. Baricault L, Denariaz G, Houri JJ, et al. Use of HT-29, a cultured human colon cancer cell line, to study the effect of fermented milks on colon cancer cell growth and differentiation. Carcinogenesis 1995;16:245-52.
37. Marin ML, Tejada-Simon MV, Lee JH, et al. Stimulation of cytokine production in clonal macrophage and T-cell models by Streptococcus thermophilus: Comparison with Bifidobacterium sp. and Lactobacillus bulgaricus. J Food Prot 1998;61:859-64.
38. Miettinen M, Lehtonen A, Julkunen I, et al. Lactobacilli and streptococci activate NF-κβ and STAT signaling pathways in human macrophages. J Immunol 2000;164:3733-40.
39. Tejada-Simon MV, Ustunol Z, Pestka JJ. Ex vivo effects of lactobacilli, streptococci, and bifidobacteria ingestion on cytokine and nitric oxide production in a murine model. J Food Prot 1999;62:162-9.
40. Pallone F, Fais S, Squarcia O, et al. Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease. In vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens. Gut 1987;28:745-53.
41. Choy MY, Walker-Smith JA, Williams CB, et al. Differential expression of CD25 (interleukin-2 receptor) on lamina propria T cells and macrophages in the intestinal lesions in Crohn's disease and ulcerative colitis. Gut 1990;31:1365-70.
42. Schreiber S, MacDermott RP, Raedler A, et al. Increased activation of isolated intestinal lamina propria mono-nuclear cells in inflammatory bowel disease. Gastroenterology 1991;101:1020-30.
43. Mariani P, Bachetoni A, D'Alessandro M, et al. Effector Th-1 cells with cytotoxic function in the intestinal lamina propria of patients with Crohn's disese. Dig Dis Sci 2000;45:2029-35.